LivaNova PLC - Ordinary Shares (LIVN): Price and Financial Metrics
GET POWR RATINGS... FREE!
LIVN POWR Grades
- Value is the dimension where LIVN ranks best; there it ranks ahead of 69.37% of US stocks.
- The strongest trend for LIVN is in Stability, which has been heading up over the past 179 days.
- LIVN ranks lowest in Momentum; there it ranks in the 19th percentile.
LIVN Stock Summary
- The price/operating cash flow metric for LivaNova PLC is higher than 87.5% of stocks in our set with a positive cash flow.
- With a year-over-year growth in debt of -60.53%, LivaNova PLC's debt growth rate surpasses only 5.39% of about US stocks.
- In terms of volatility of its share price, LIVN is more volatile than only 14.08% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to LivaNova PLC are FARO, OSUR, INTZ, QUMU, and SMWB.
- Visit LIVN's SEC page to see the company's official filings. To visit the company's web site, go to www.livanova.com.
LIVN Valuation Summary
- LIVN's EV/EBIT ratio is -13.3; this is 145.39% lower than that of the median Healthcare stock.
- Over the past 71 months, LIVN's price/earnings ratio has gone down 83.7.
- LIVN's price/earnings ratio has moved down 83.7 over the prior 71 months.
Below are key valuation metrics over time for LIVN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
LIVN | 2021-08-31 | 4.0 | 3.9 | -10.7 | -13.3 |
LIVN | 2021-08-30 | 4.0 | 3.9 | -10.6 | -13.3 |
LIVN | 2021-08-27 | 4.0 | 3.9 | -10.7 | -13.4 |
LIVN | 2021-08-26 | 3.9 | 3.8 | -10.5 | -13.2 |
LIVN | 2021-08-25 | 4.0 | 3.9 | -10.7 | -13.4 |
LIVN | 2021-08-24 | 4.0 | 3.9 | -10.8 | -13.4 |
LIVN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LIVN has a Quality Grade of C, ranking ahead of 45.21% of graded US stocks.
- LIVN's asset turnover comes in at 0.441 -- ranking 110th of 186 Medical Equipment stocks.
- XRAY, PDEX, and ZBH are the stocks whose asset turnover ratios are most correlated with LIVN.
The table below shows LIVN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.441 | 0.662 | -0.416 |
2021-06-30 | 0.421 | 0.653 | -0.308 |
2021-03-31 | 0.383 | 0.654 | -0.262 |
2020-12-31 | 0.378 | 0.662 | -0.271 |
2020-09-30 | 0.385 | 0.683 | -0.167 |
2020-06-30 | 0.397 | 0.690 | -0.156 |
LIVN Price Target
For more insight on analysts targets of LIVN, see our LIVN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $100.71 | Average Broker Recommendation | 1.43 (Moderate Buy) |
LIVN Stock Price Chart Interactive Chart >
LIVN Price/Volume Stats
Current price | $64.87 | 52-week high | $93.89 |
Prev. close | $64.33 | 52-week low | $58.18 |
Day low | $62.44 | Volume | 265,400 |
Day high | $65.05 | Avg. volume | 346,620 |
50-day MA | $76.28 | Dividend yield | N/A |
200-day MA | $79.99 | Market Cap | 3.47B |
LivaNova PLC - Ordinary Shares (LIVN) Company Bio
LivaNova PLC. offers cardiac surgery, cardiac rhythm management, and neuromodulation related products worldwide. The company was founded in 1987 and is based in London, England.
Latest LIVN News From Around the Web
Below are the latest news stories about LivaNova PLC that investors may wish to consider to help them evaluate LIVN as an investment opportunity.
LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep ApneaLONDON, February 24, 2022--LivaNova PLC announced the first patient implanted in clinical study, "Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation." |
LivaNova (LIVN) Surpasses Q4 Earnings and Revenue EstimatesLivaNova (LIVN) delivered earnings and revenue surprises of 14% and 2.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
LivaNova Reports Fourth-Quarter and Full-Year 2021 ResultsLONDON, February 23, 2022--LivaNova PLC today reported results for the quarter and full year ended December 31, 2021. |
Top 10 Biotech Stocks to Buy According to Jeremy Green’s Redmile GroupIn this article, we will discuss the top 10 biotech stocks to buy according to Jeremy Green’s Redmile Group. If you want to skip our detailed analysis of Green’s history, investment philosophy performance, you can go directly to the Top 5 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group. Jeremy Green is the […] |
Were Hedge Funds Right About LivaNova PLC (LIVN)?Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January. |
LIVN Price Returns
1-mo | -20.80% |
3-mo | N/A |
6-mo | -24.83% |
1-year | -20.28% |
3-year | -9.09% |
5-year | 11.77% |
YTD | -25.80% |
2021 | 32.05% |
2020 | -12.22% |
2019 | -17.54% |
2018 | 14.45% |
2017 | 77.72% |
Continue Researching LIVN
Want to do more research on LivaNova PLC's stock and its price? Try the links below:LivaNova PLC (LIVN) Stock Price | Nasdaq
LivaNova PLC (LIVN) Stock Quote, History and News - Yahoo Finance
LivaNova PLC (LIVN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...